Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

New data supporting gradual up-titration of ponesimod to mitigate first-dose cardiodynamic effects to be presented at EACPT 2015 (Actelion Ltd)

$
0
0
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 25 June 2015 - Actelion Ltd (SIX: ATLN) today announced that data supporting a gradual up-titration dose regimen of ponesimod will be presented at the 12th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT 2015). The congress will take place in Madrid, Spain from the 27-30 June 2015 and the poster abstract can be found on page 37 of the . The poster presentation summarizes the results of a clinical study comparing the effects of ponesimod on heart rate and AV-conduction using a new gradual up-titration regimen verses the up-titration regimen previously used in clinical investigation. The ponesimod...

Viewing all articles
Browse latest Browse all 480

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>